Skip to main content
Premium Trial:

Request an Annual Quote

Mobidiag C. difficile Test Receives CE Mark

NEW YORK (GenomeWeb) — Finland's Mobidiag announced today that its qualitative qPCR-based Clostridium difficile infection (CDI) test has received CE-IVD marking and is now available throughout Europe.

Called Amplidiag C. difficile+27, the test is able to detect CDI in stool samples by identifying the toxin B gene (tcdB), as well as differentiate the hypervirulence-associated 027 ribotype, in a single reaction.

In a study evaluating the test in 309 prospective and 35 spiked samples against toxigenic stool culture findings and independent molecular methods, it showed 100 percent specificity for both tcdB and the 027 ribotype, and sensitivities of 97.8 percent and 94.4 percent, respectively.

"CDI is a major cause of mortality and increased healthcare costs globally," Mobidiag CEO Tuomas Tenkanen said in a statement. "Early identification is important for guiding patient management and infection control measures … [as well as] lowering the overall healthcare costs of CDI."

The Scan

Study Reveals New Details About Genetics of Major Cause of Female Infertility

Researchers in Nature Medicine conducted a whole-exome sequencing study of mote than a thousand patients with premature ovarian insufficiency.

Circulating Tumor DNA Shows Potential as Biomarker in Rare Childhood Cancer

A study in the Journal of Clinical Oncology has found that circulating tumor DNA levels in rhabdomyosarcoma may serve as a biomarker for prognosis.

Study Recommends Cancer Screening for Dogs Beginning Age Seven, Depending on Breed

PetDx researchers report in PLOS One that annual cancer screening for dogs should begin by age seven.

White-Tailed Deer Harbor SARS-CoV-2 Variants No Longer Infecting Humans, Study Finds

A new study in PNAS has found that white-tailed deer could act as a reservoir of SARS-CoV-2 variants no longer found among humans.